RxDoctor Payments Data

Henry Novack, MD

Cardiovascular Disease · New York, NYNPI 1760460299

Payments from drug & device makers

$1,972in general payments, 2019–2025

Across 117 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$433
  • Amgen$322
  • Novartis$192
  • AstraZeneca$187
  • Amarin Pharma, Inc.$180
  • Pfizer$126
  • plus $532 from 11 others

What the payments were for

  • Food & beverage$1,78791%
  • Education$1859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,972 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$221,185
Medicare patients
799
Services billed
2,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$357,892
Repatha SureclickEvolocumab117$82,731
XareltoRivaroxaban58$72,890
EntrestoSacubitril/Valsartan62$64,027
JardianceEmpagliflozin58$62,244
Praluent PenAlirocumab48$23,905
FarxigaDapagliflozin Propanediol13$21,844
TrulicityDulaglutide12$15,594
MultaqDronedarone Hcl11$14,274
Ezetimibe447$10,696
Rosuvastatin Calcium598$8,668
VascepaIcosapent Ethyl11$7,363
Metoprolol Succinate474$6,715
BrilintaTicagrelor12$5,984
Atorvastatin Calcium465$4,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$357,892431 claims
Johnson & JohnsonXarelto$86$72,89058 claims
Boehringer IngelheimJardiance, Pradaxa$433$64,52969 claims
NovartisEntresto$192$64,02762 claims
AstraZenecaFarxiga, Brilinta$187$27,82825 claims
Sanofi-aventis U.S. LLCMultaq$66$14,27411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →